Cadila Healthcare on Friday reported a 65.26 per cent fall in its consolidated net profit to Rs 138.4 crore for the quarter ended June 30, 2017 as compared to Rs 398.4 crore in the year-ago period.
Its total revenue from operations stood at Rs 2,228.8 crore, down by 4.4 per cent from Rs 2,333.1 crore for the year-ago period.
The company said it has received the tentative approval from USFDA to "market Mesalamine Suppositories for rectal use". Mesalamine is used to treat an inflammatory bowel disease, such as ulcerative colitis.
"It will be produced at the group's Topical plant here, the company added.
--IANS
bdc/vgu/vm
Disclaimer: No Business Standard Journalist was involved in creation of this content
